https://ecancer.org/en/video/10447-adagrasib-shows-cns-penetration-and-encouraging-intracranial-activity-for-krasg12c-mutated-nsclc-and-active-untreated-cns-metastases
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC...
Dr Joshua Sabari speaks to ecancer about the KRYSTAL-1 trial which studied the activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and activ
adagrasibshowscnspenetrationencouraging
https://dzl.de/klinische-studien/a-randomized-double-blind-phase-3-trial-of-adagrasib-plus-pembrolizumab-plus-chemotherapy-vs-placebo-plus-pembrolizumab-plus-chemotherapy-in-participants-with-previously-untreated-locally-advanced/
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs....
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus...
double blindphasetrialadagrasibplus
https://synapse.patsnap.com/drug/f5c9936fda1546bb9a0be9fee5d9e248
Adagrasib - Drug Targets, Indications, Patents - Synapse
drug targetsadagrasibindicationspatentssynapse
https://www.cancernetwork.com/approval-alert/adagrasib-cetuximab-in-kras-g12c-mutated-colorectal-cancer
Adagrasib/Cetuximab in KRAS G12C-Mutated Colorectal Cancer | Approval Alert | CancerNetwork
colorectal canceradagrasibkrasmutatedapproval
https://www.mednet.nl/congres-nieuws/adagrasib-verbetert-pfs-ten-opzichte-van-docetaxel-bij-eerder-behandeld-kras-g12c-nsclc/
Adagrasib verbetert PFS ten opzichte van docetaxel bij eerder behandeld KRAS G12C+ NSCLC | MedNet
Adagrasib behandeling verbetert significant progressievrije overleving en objectieve respons bij eerder behandelde KRAS G12C-gemuteerde NSCLC.
adagrasibpfstenvanbij